HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

NCT05864755 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Unrescetable Hepatocellular Carcinoma

Interventions

DRUG: HAIC+Durvalumab+Tremelimumab+Bevacizumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital